Clomethiazole Hcl

Adjusting pre-compression force to 2.5 kN and main compression force to 12 kN on a 45-station Korsch XL 400 rotary press equipped with 9 mm round concave tooling effectively accommodates the brittle fracture propensity of the directly compressible grade. The formulation comprises Clomethiazole HCl (sieved through a 500 µm screen) at 30.0 wt%, microcrystalline cellulose PH-102 (55.0 wt%), croscarmellose sodium (3.0 wt%), partially pregelatinised maize starch (10.0 wt%), colloidal silicon dioxide (1.0 wt%), and magnesium stearate (1.0 wt%) added after 15 min of tumble blending in a 300 L bin blender at 12 rpm. Pre-mix of colloidal silicon dioxide with the drug substance serves to eliminate electrostatic adhesion to vessel walls, a documented flow impediment when relative humidity exceeds 35% during fluidisation. Blend uniformity is validated per PDA Technical Report No. 25 using stratified sampling across 10 positions, with acceptance criteria of individual assay 90.0–110.0% label claim and RSD ≤ 5.0%. Tablets are compressed to a target weight of 300 mg and hardness of 60–100 N, achieving a friability below 0.3% (Ph. Eur. 2.9.7) and disintegration within 5 minutes in water at 37 °C (Ph. Eur. 2.9.1). The immediate-release tablet complies with dissolution criterion of Q ≥ 80% after 30 minutes in 900 mL of 0.01 N HCl using Apparatus 2 at 50 rpm (Ph. Eur. 2.9.3). A process analytical technology framework monitors compaction force drift; out-of-trend values above 13 kN trigger a tablet weight excursion of ± 5%, necessitating an automatic rejection gate at the press. Residual moisture of the finished tablet must not exceed 1.0% w/w, as higher levels accelerate hydrochloride salt hydrolysis, generating a des-chloro degradant detected by HPLC at relative retention time 0.85. Manufacture is conducted within an OEB 3 containment isolator; the drug substance is manufactured under EU GMP Part II and a technical dossier equivalent to an ASMF is maintained. Release specifications include identification by IR, assay 95.0–105.0%, related substances (individual unspecified impurity ≤ 0.10%, total impurities ≤ 0.5%) by HPLC in accordance with Ph. Eur. 2.2.29, and residual solvents per Ph. Eur. 5.4. The finished product is packaged in HDPE bottles with desiccant canisters and labelled “protect from light.”

A direct comparison of drug product attributes for the two principal solid dosage processing routes reveals where the direct compression route shows faster dissolution but slightly higher moisture sensitivity, while the wet granulation route gains in hardness and chemical stability over accelerated storage.

What shear rate thresholds during high-shear wet granulation minimise amorphous content to prevent dose dumping upon accelerated storage?

Process data from a Diosna P1-6 equipped with a 2.5 L bowl and a chopper speed set to 1,500 rpm indicate that maintaining impeller tip speed between 3.0 m/s and 4.0 m/s during the aqueous binder addition phase keeps the temperature rise below 8 °C, thereby limiting partial dissolution and subsequent recrystallization of Clomethiazole HCl into amorphous domains. In this formulation, Clomethiazole HCl at 40.0 wt% is dry-mixed with lactose monohydrate (45.0 wt%), maize starch (10.0 wt%), and povidone K30 (3.5 wt%) for 3 minutes at 200 rpm impeller speed. Granulating fluid is purified water dosed at 1.5% of dry mass per second via a 2 mm nozzle, targeting a final water content of 12–15% w/w. Wet mass is passed through a 1.6 mm screen and dried in a Glatt GPCG 3.1 fluid-bed dryer with inlet air temperature 55 °C until loss on drying reaches 1.8–2.2%. The dried granules are calibrated through a 1.0 mm sieve and blended with 2.0 wt% crospovidone and 1.0 wt% magnesium stearate prior to compression on a 27-station Fette 2090i press at 15 kN. Dissolution stability studies at 40 °C / 75% RH for 6 months show F2 similarity values above 50 only when the impeller power consumption end-point is controlled within 18–22% of the baseline dry-mix level, preventing overdosing of mechanical energy that generates fines and fused agglomerates possessing variable porosity. The terminal film-coated tablet is subjected to an acid-stage dissolution test with an acceptance criterion of Q ≥ 75% at 45 minutes to detect any premature gelling caused by povidone-rich surfaces. All sampling and in-process controls align with ASTM E2500-20 risk-based verification strategies, and the coating operation uses a pan speed of 4–8 rpm and Opadry II aqueous dispersion at 12% solids, achieving a 3% weight gain with a target surface roughness Ra < 1.5 µm. The drug product analytical release method for related substances uses a gradient HPLC method validated per ICH Q2(R1), with limits harmonised to published literature for clomethiazole edisylate. An out-of-specification investigation procedure is triggered whenever total impurities exceed 0.5% or an unknown impurity exceeds 0.20%.

Overkill sterilization cycle design for Clomethiazole HCl injection in 5-mL ampoules

A 2.0-bar overpressure air-steam mixture cycle at 121 °C for 15 minutes was selected for 5 mL Type I amber glass ampoules after heat distribution studies in an autoclave with a 12 m³ chamber capacity revealed cold spots at the drain and door zones offset by 1.2 °C during the come-up phase. The bulk solution preparation combines Clomethiazole HCl equivalent to 5.0 mg/mL free base dissolved in Water for Injection at 25 °C with 0.1 N hydrochloric acid or 1 M sodium hydroxide to achieve a pH of 4.0–4.5, a range where solubility remains above 50 mg/mL and hydrolytic degradation is retarded as demonstrated by kinetic modelling at pH 2–6 and 80 °C. The solution is sparged with pharmaceutical-grade nitrogen to keep dissolved oxygen below 0.5 ppm prior to passage through a 0.22 µm PVDF filter and filling under nitrogen overlay using a B+S SFM 5110 filling and sealing machine at 300 units/min. The amber glass provides light protection compliant with Ph. Eur. 3.2.1 and the ampoule dimensions follow ISO 9187-1. Terminal sterilization lethality is validated to achieve an SAL of ≤ 10⁻⁶ using biological indicators Geobacillus stearothermophilus ATCC 7953 with a starting population of ≥ 10⁶ spores per carrier. Post-sterilization, the ampoules are subjected to leak testing by high-voltage inspection at 25 kV. A 100% visual inspection is performed according to Ph. Eur. 2.9.20 with AQL set to 0.065% for critical defects. The finished product assay limits are 95.0–105.0%, with N-nitroso impurities controlled to < 1 ppm following EMA/409815/2020 guidance. Batch records log the F₀ value calculated by an Ellab TrackSense Pro system; any cycle with F₀ below 12 min triggers automatic rejection. The ampoule label states “single-dose container” and bears the symbol for light protection per ISO 15223-1.

When a lyophilized plug requires reconstitution in Sterile Water for Injection to yield a 5 mg/mL solution for intravenous infusion, the drug substance is first dissolved in a cryoprotectant-containing vehicle at a concentration of 20 mg/mL during bulk compounding. The formulation comprises Clomethiazole HCl, mannitol (50 mg/mL) as a bulking agent, and 0.1% w/v of the antioxidant monothioglycerol, adjusted to pH 4.0 with 0.05 M citric acid and sodium citrate buffer system. Dissolution is performed in a 316L stainless steel vessel under nitrogen blanketing; the batch is cooled to 2–8 °C to suppress thermal degradation prior to aseptic filtration through a redundant 0.22 µm filter cascade. Glass vials (Type I, 10 mL nominal capacity) are washed, depyrogenated at 250 °C for 45 minutes, and filled to a target volume of 5.5 mL to account for stopper absorption. The lyophilization cycle in a Telstar LyoBeta 15 freeze dryer employs shelf freezing at −45 °C for 4 hours, primary drying at −20 °C and 0.1 mbar chamber pressure for 24 hours, and secondary drying at 25 °C with 0.05 mbar until residual moisture by Karl Fischer titration drops below 1.0%. Collapse temperature of the formulation was measured by freeze-drying microscopy at −28 °C; primary drying shelf temperature is maintained at least 5 °C below Tg' to avoid matrix collapse. Post-lyophilization, vials are stoppered under slight vacuum and sealed with aluminium flip-off caps. Reconstitution time is tested after storage at 25 °C / 60% RH and must not exceed 90 seconds. The lyophilized cake acceptance criteria include appearance of a white to off-white intact cake, residual moisture ≤ 1.0%, and reconstituted solution clarity ≤ Reference Suspension II (Ph. Eur. 2.2.2). Process validation batches demonstrate a critical process parameter limit for the shelf cooling rate: ramps faster than 0.5 °C/min induce dendritic ice formation that entrains drug-rich domains, resulting in pocketing and a 4-log endotoxin recovery failure in LAL testing. All steps comply with FDA 21 CFR Part 211 and Annex 1 to the EudraLex Volume 4, and the facility operates within a Grade A/B clean room with EM monitoring based on ISO 14644-1 Class 5.

When an oral multi-dose liquid requires a validated preservative efficacy test, which excipient combinations remain compatible with the hydrochloride salt?

Systematic screening of benzoic acid (0.05–0.15% w/v), sodium benzoate (0.1%), potassium sorbate (0.1%), and methyl parahydroxybenzoate (0.08%) in a vehicle containing sorbitol 35% w/v, glycerol 10% w/v, and a raspberry flavour system at pH 4.0 identified a combination of 0.1% sodium benzoate and 0.06% methyl parahydroxybenzoate as the only pairing that delivers a 5-log reduction in Pseudomonas aeruginosa ATCC 9027 within 24 hours while maintaining Clomethiazole HCl chemical stability over 12 months at 25 °C. The syrup is manufactured by dissolving Clomethiazole HCl in a portion of purified water at 40 °C before addition to the pre-melted sorbitol-glycerol base to avoid localised acidic pockets that cause pH spikes and dimer impurity formation. The final concentration of Clomethiazole HCl corresponds to 50 mg/5 mL free base. The batch volume of 1,000 L is processed in a 316L vessel with a bottom magnetic stirrer at 150 rpm; after achieving homogeneity, the preservatives are added as a pre-dissolved concentrate. The liquid is passed through a 5 µm cartridge filter and filled under nitrogen into amber PET bottles fitted with child-resistant dropper closures. Preservative efficacy testing follows Ph. Eur. 5.1.3 criteria A for oral preparations. Routine release tests include density at 20 °C (Ph. Eur. 2.2.5), pH (Ph. Eur. 2.2.3), assay by HPLC (Ph. Eur. 2.2.29), and microbiological quality TAMC 10² CFU/g, TYMC 10 CFU/g (Ph. Eur. 5.1.4). Stability-indicating studies with forced degradation using 0.1 M HCl, 0.1 M NaOH, and 3% H₂O₂ confirm the method’s capability to separate all known degradants. The product is labelled for use within 28 days after first opening; in-use stability testing at 30 °C / 65% RH demonstrated no individual impurity exceeding 0.2%. A challenge with the nitrosating agent showed no formation of N-nitrosamines above 10 ppb, satisfying the EMA Q&A for nitrosamines. This liquid formulation is supplied in a carton bearing a tamper-evident seal and the instruction “shake well before use.”